As a competitor in the kidney care market, DaVita Inc. could potentially face increased competition due to the potential benefits of GLP-1 drugs, including Novo Nordisk's Ozempic, in slowing the progression of chronic kidney disease and reducing overall mortality. This could negatively impact DaVita's market share and stock price in the short term.

Fresenius Medical Care's statement about the potential benefits of GLP-1 drugs, including Novo Nordisk's Ozempic, could enhance its reputation as a knowledgeable and reliable source of information in the healthcare sector. This could potentially attract more investors and customers, positively impacting its stock price in the short term.

The statement from Fresenius Medical Care about the potential benefits of Novo Nordisk's Ozempic in slowing the progression of chronic kidney disease and reducing overall mortality could lead to increased demand for the drug. This could positively impact Novo Nordisk's revenues and stock price in the short term.